Drug Trial Radar · NCT07768254
A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Sep 9, 2026
Primary completion
Apr 15, 2028
Study completion Apr 15, 2028
Sponsor
- Lead sponsor
- Helixon Biotechnology (Suzhou) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HX15001 injection combined with Etrasimod tablets in participants with moderately to severely active ulcerative colitis (UC).
Conditions
- Colitis, Ulcerative
Interventions
Biological: HX15001Drug
Dose 1: HX15001
Biological: HX15001Drug
Dose 2: HX15001
Biological: HX15001Drug
Dose 3: HX15001
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint in the study is the rate of participants with adverse events , serious adverse events, adverse events leading to study withdrawal, and clinically significant abnormalityes in vital signs, ECG, and laboratory test values.Time frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The first affiliated hospital of Anhui medical university
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.